Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Paul Mulholland

1-50 of 58 results

View this query on the Wikidata Query Service
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

scientific article
Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastati

scientific article published on 01 February 2000
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

scientific article
Technical and implementation issues in using next-generation sequencing of cancers in clinical practice

scientific article published on July 25, 2013
Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme.

scientific article published on April 2006
Expression of Idh1(R132H) in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis

scientific article published on 21 September 2016
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma

scientific article published on May 23, 2011
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

scientific article published on 25 May 2016
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets

scientific article
Ipilimumab and Bevacizumab in Glioblastoma.

scientific article
Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.

scientific article published in November 2003
Harnessing the immune system in glioblastoma

scientific article published on 05 November 2018
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

scientific article published on 13 August 2018
Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study

scientific article published on 27 June 2013
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

scientific article published on 26 October 2016
Cisplatin and gemcitabine in the management of metastatic penile cancer.

scientific article published on 4 February 2008
Antibody-targeted nanoparticles for cancer treatment

scientific article
Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix

scientific article published on 01 September 1999
p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.

scientific article published on 9 September 2016
Dabrafenib and trametinib in BRAFV600E mutated glioma

scientific article published on 6 October 2017
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma

scientific article
Three different brain tumours evolving from a common origin

scientific article published on April 2013
Prolonging the circulatory retention of SPIONs using dextran sulfate: in vivo tracking achieved by functionalisation with near-infrared dyes.

scientific article published in January 2014
Fucoidan Prolongs the Circulation Time of Dextran-Coated Iron Oxide Nanoparticles

scientific article published on 17 January 2018
A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.

scientific article
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

scientific article
Adjuvant Chemotherapy is Indicated in Patients with Lower Grade Glioma.

scientific article
Combining Ipilimumab and Bevacizumab in Glioblastoma: Is it Really Safe and Effective? Author Response.

scientific article published on 27 July 2016
AIDS-related Kaposi's sarcoma in a patient with a normal CD4 count

scientific article published on 22 October 2007
Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

NCOG-08. NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMAS

scientific article published on 6 November 2017
ATIM-20. CLINICAL OUTCOMES WITH IPILIMUMAB IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECENTLY DIAGNOSED GLIOBLASTOMA - A RETROSPECTIVE COHORT REVIEW

ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF 11C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGING.

scientific article
Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

QLIF-12. HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091)

scientific article published on 6 November 2017
Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

TMIC-33. POTENTIAL OF MAGNETIC HYPERTHERMIA TO STIMULATE AN IMMUNE RESPONSE IN GLIOBLASTOMA

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/WO BEVACIZUMAB IS DEPENDENT ON , AND CIMP STATUS, BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL

scientific article published on 6 November 2017
OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma.

scientific article published on 21 September 2016
Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

scientific article published on 12 March 2020
Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Paulina is supported by:

About Paulina

Help